Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$62.61+1.87%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put PCVX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskNot enough reads yet
PCVX’s central bet is VAX-31’s Phase 3 OPUS trials, not demonstrated revenue growth. The latest quarter missed GAAP EPS consensus by 34%, with revenue growth data unavailable. No clean valuation multiple is available, so the desk cannot define a peer-multiple comparison. The price is roughly in line with forecast growth, though trial progress supports the VAX-31 case. The next-quarter miss probability is 68%, and a dual offering may dilute shares. Peer multiples imply a price about 49% above where it trades. Our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. PCVX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering PCVX (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for PCVX in the last 4 months.
Continue this research
Compare PCVX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PCVX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PCVX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain Strong Cash Position to Support Growth
Equity offering may dilute shares and impact cash position.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $62.61
The last 12 months of price, then the range of analyst 12-month targets from today’s $62.61.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Maintain Strong Cash Position to Support Growth
Strengthens cash position for growth initiatives.
Advances: Complete VAX-31 Phase 3 OPUS Trials and Report Data
BofA's target raise reflects confidence in OPUS Trials.
Threatens: Maintain Strong Cash Position to Support Growth
Dual offering may strain cash position.
Advances: Complete VAX-31 Phase 3 OPUS Trials and Report Data
Phase 3 trial data presentation supports VAX-31 progress.
Threatens: Maintain Strong Cash Position to Support Growth
High cash burn raises concerns about financial stability.
Advances: Initiate VAX-31 Adult Pivotal Study
Narrowing guidance indicates progress in VAX-31 development.
Advances: Initiate VAX-31 Adult Pivotal Study
Completion of enrollment is a significant milestone for VAX-31.